Automated Insulin Delivery Improves Glycemia, Not Yet Perinatal Outcomes
This integrative review clarifies that automated insulin delivery benefits in type 1 diabetes pregnancy are system-specific and centered on glucose metrics, giving Women's Health pharmacists a device-by-device framework for counseling and implementation.
Automated insulin delivery transforms diabetes management in pregnancy.
Automated insulin delivery (AID) systems have significant potential to improve glycemic control during pregnancy in individuals with type 1 diabetes, enhancing maternal and neonatal health outcomes. The review highlights system-specific evidence for improved continuous glucose monitoring outcomes with AID systems like CamAPS FX and MiniMed 780G, but notes gaps in long-term maternal and neonatal data. The study underscores the need for equitable implementation of AID systems, considering algorithm design, user interaction, and access to specialist care, while acknowledging existing evidence limitations. AID systems can significantly enhance pregnancy outcomes in type 1 diabetes, but require careful socio-technical assessment for equitable use.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Li J, Qi TN, Tan X, Jayasekara R
Citation:Li J, Qi TN, Tan X, et al. Automated Insulin Delivery in Pregnancy With Type 1 Diabetes: An Integrative Review of Clinical Evidence, Socio-Technical Implementation and Equity. Journal of diabetes research. 2026;2026(1):e1989683. doi:10.1155/jdr/1989683